Journal
CELL REPORTS
Volume 15, Issue 9, Pages 1973-1985Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2016.04.081
Keywords
-
Categories
Funding
- ZonMW [43400003]
- VIDI-ZonMW [917.11.337]
- KWF [UU 2010-4669, UU 2013-6426, UU 2014-6790, UU 2015-7601]
- Vrienden van het UMCU
- AICR [10-0736, 15-0049]
- NIH [R01 AI115471]
- Lady Tata Memorial Trust
- Dutch Cancer Society (KWF) [UU 2012-5667]
- Worldwide Cancer Research [15-0049] Funding Source: researchfish
Ask authors/readers for more resources
Human V gamma 9V delta 2 T cells respond to tumor cells by sensing elevated levels of phosphorylated intermediates of the dysregulated mevalonate pathway, which is translated into activating signals by the ubiquitously expressed butyrophilin A1 (BTN3A1) through yet unknown mechanisms. Here, we developed an unbiased, genome-wide screening method that identified RhoB as a critical mediator of V gamma 9V delta 2 TCR activation in tumor cells. Our results show that V gamma 9V delta 2 TCR activation is modulated by the GTPase activity of RhoB and its redistribution to BTN3A1. This is associated with cytoskeletal changes that directly stabilize BTN3A1 in the membrane, and the subsequent dissociation of RhoB from BTN3A1. Furthermore, phosphoantigen accumulation induces a conformational change in BTN3A1, rendering its extracellular domains recognizable by V gamma 9V delta 2 TCRs. These complementary events provide further evidence for inside-out signaling as an essential step in the recognition of tumor cells by a V gamma 9V delta 2 TCR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available